Metoprolol Drug Review: PTCB Exam Study Notes

Metoprolol Overview for the PTCB Exam

Metoprolol is one of the most commonly prescribed beta blockers and a frequently tested drug on the PTCB certification exam. It comes in two distinct formulations with different brand names, which is a common source of confusion and exam questions.

Brand Names and Formulations

Metoprolol is available in two salt forms:

Metoprolol tartrate: Brand name Lopressor. Immediate-release, typically dosed twice daily.
Metoprolol succinate: Brand name Toprol-XL. Extended-release, dosed once daily.

This distinction is critical for the PTCB exam. The two formulations are not interchangeable. Dispensing the wrong salt form is a medication error.

Drug Classification

Metoprolol is a selective beta-1 adrenergic blocker (cardioselective beta blocker). Beta blockers are identified by the suffix -olol. Other beta blockers include atenolol (Tenormin), propranolol (Inderal), and carvedilol (Coreg). Cardioselective beta blockers primarily affect the heart (beta-1 receptors) rather than the lungs (beta-2 receptors).

Mechanism of Action

Metoprolol blocks beta-1 adrenergic receptors in the heart, reducing heart rate, cardiac contractility, and cardiac output. This results in lower blood pressure, reduced myocardial oxygen demand, and decreased workload on the heart. At higher doses, selectivity may be lost and beta-2 blockade can occur.

Common Indications

Hypertension: First-line or add-on therapy for high blood pressure
Heart failure: Metoprolol succinate specifically is approved for stable heart failure
Angina pectoris: Reduces frequency of chest pain episodes
Post-myocardial infarction: Reduces mortality after heart attack
Arrhythmias: Controls heart rate in atrial fibrillation and other tachyarrhythmias

Side Effects

Bradycardia: Slow heart rate, the most predictable pharmacological effect
Hypotension: Low blood pressure, especially when starting therapy
Fatigue and dizziness: Common, especially during dose titration
Cold extremities: Due to reduced peripheral blood flow
Depression and sleep disturbances: Reported in some patients
Bronchospasm: Less likely with cardioselective agents but possible at high doses

Important Warnings

Beta blockers should never be stopped abruptly. Sudden discontinuation can cause rebound tachycardia, hypertension, and in patients with coronary artery disease, angina or myocardial infarction. Doses should be tapered gradually over 1 to 2 weeks. This is a commonly tested PTCB exam concept.

PTCB Exam Tips

Remember: metoprolol tartrate is Lopressor (twice daily), metoprolol succinate is Toprol-XL (once daily), beta blockers end in -olol, do not stop abruptly, and the key side effect is bradycardia. Practice at PTCBprep.